Pharma giant AstraZeneca has added another new target for idiopathic pulmonary fibrosis (IPF) to its drug portfolio, which was identified by London-based AI drug discovery company BenevolentAI by leveraging its AI-powered target discovery platform. BenevolentAI will receive a milestone payment as part of the agreement.
<ul><li>The novel target is the third one to enter the pharma giant’s drug portfolio through the collaboration initiated by the two parties in April 2019 to identify potential targets for IPF and chronic kidney disease (CKD). The duo also extended the partnership’s focus to two additional disease areas—systemic lupus erythematosus and heart failure—in January 2022.</ul>
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.